Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Afimetoran · 3 trials · 3 indications
Parts 1 and 2
| Arm | Type | Description |
|---|---|---|
| Afimetoran: Dose 1 | EXPERIMENTAL | - |
| Afimetoran: Dose 2 | EXPERIMENTAL | - |
| Afimetoran: Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Afimetoran, followed by famotidine + afimetoran | EXPERIMENTAL | - |
| Famotidine + afimetoran, followed by afimetoran | EXPERIMENTAL | - |
| Afimetoran | EXPERIMENTAL | - |
| Famotidine, followed by afimetoran | EXPERIMENTAL | - |
| Part 1: Afimetoran followed by phenytoin + afimetoran | EXPERIMENTAL | - |
| Part 2: Midazolam followed by afimetoran + midazolam | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Afimetoran | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
| Famotidine | DRUG | Specified dose on specified days |
| Phenytoin | DRUG | Specified dose on specified days |
| Midazolam | DRUG | Specified dose on specified days |
Inclusion Criteria: * Diagnosed ≥ 12 weeks before the screening visit and qualify as having SLE according to the SLE International Collaborating Clinics (SLICC) Classification Criteria at the screening visit * Test positive, as determined by the central laboratory, for at least one of the following...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
Afimetoran is an investigational small molecule being studied for the treatment of Systemic Lupus Erythematosus (SLE). It is also being evaluated in healthy volunteers and healthy participants in drug interaction studies. The drug is currently in clinical development and is not approved by the FDA.
Afimetoran is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's efficacy, safety, and pharmacokinetics in patients with Systemic Lupus Erythematosus and in healthy participants.
Afimetoran is in clinical development. A Phase 2 trial in Systemic Lupus Erythematosus is active but not recruiting participants, and two Phase 1 drug interaction studies in healthy participants have been completed. The drug remains investigational and has not received FDA approval.
Afimetoran is being studied in three clinical trials. NCT04895696 is a Phase 2 trial in Systemic Lupus Erythematosus with 248 participants, active but not recruiting. NCT05866627 is a completed Phase 1 study in healthy volunteers, and NCT05901714 is a completed Phase 1 study in healthy participants.
Afimetoran is also known as BMS-986256. This alternative name is used in some research contexts. The drug is being developed by Bristol-Myers Squibb for Systemic Lupus Erythematosus and is currently in Phase 2 clinical trials.